相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The right Timing, right combination, right sequence, and right delivery for Cancer immunotherapy
Minsu Kwon et al.
JOURNAL OF CONTROLLED RELEASE (2021)
Radiotherapy, immunotherapy, and the tumour microenvironment: Turning an immunosuppressive milieu into a therapeutic opportunity
N. E. Donlon et al.
CANCER LETTERS (2021)
NER-factor DDB2 regulates HIF1α and hypoxia-response genes in HNSCC
Prashant Bommi et al.
ONCOGENE (2020)
Immune-related gene signature for predicting the prognosis of head and neck squamous cell carcinoma
Yangyang She et al.
CANCER CELL INTERNATIONAL (2020)
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
Anthony R. Cillo et al.
IMMUNITY (2020)
Cancer associated fibroblasts confer shear resistance to circulating tumor cells during prostate cancer metastatic progression
Nerymar Ortiz-Otero et al.
Oncotarget (2020)
The Immune Microenvironment in Head and Neck Squamous Cell Carcinoma: on Subsets and Subsites
Niels E. Wondergem et al.
CURRENT ONCOLOGY REPORTS (2020)
Tumor Microenvironment and Immunotherapy Response in Head and Neck Cancer
Panagiota Economopoulou et al.
CANCERS (2020)
Characteristics of the Tumor Microenvironment That Influence Immune Cell Functions: Hypoxia, Oxidative Stress, Metabolic Alterations
Ryan C. Augustin et al.
CANCERS (2020)
Identification of a Prognostic Immune Signature for Esophageal Squamous Cell Carcinoma to Predict Survival and Inflammatory Landscapes
Chaoqi Zhang et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
Brian I. Rini et al.
LANCET (2019)
Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer
Athanassios Argiris et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness et al.
LANCET (2019)
Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy
Y. -P. Chen et al.
ANNALS OF ONCOLOGY (2019)
Stromal-Immune Score-Based Gene Signature: A Prognosis Stratification Tool in Gastric Cancer
Hao Wang et al.
FRONTIERS IN ONCOLOGY (2019)
Immunometabolic Alterations by HPV Infection: New Dimensions to Head and Neck Cancer Disparity
Sanjib Chaudhary et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Turning foes to friends: targeting cancer-associated fibroblasts
Xueman Chen et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
MDSC; the Most Important Cell You Have Never Heard Of
R. J. Tesi
TRENDS IN PHARMACOLOGICAL SCIENCES (2019)
Identification and Validation of an Immune-Related RNA Signature to Predict Survival of Patients With Head and Neck Squamous Cell Carcinoma
Shuo Wu et al.
FRONTIERS IN GENETICS (2019)
Clinical Relevance and Suppressive Capacity of Human Myeloid-Derived Suppressor Cell Subsets
Stephan Lang et al.
CLINICAL CANCER RESEARCH (2018)
Myeloid-derived suppressor cells coming of age
Filippo Veglia et al.
NATURE IMMUNOLOGY (2018)
Targeting Tumor Metabolism: A New Challenge to improve immunotherapy
Soumaya Kouidhi et al.
FRONTIERS IN IMMUNOLOGY (2018)
Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck The Active8 Randomized Clinical Trial
Robert L. Ferris et al.
JAMA ONCOLOGY (2018)
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
Peng Jiang et al.
NATURE MEDICINE (2018)
Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy
Guozhu Xie et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma
Charlotte Leduc et al.
ESMO OPEN (2018)
Involvement of local renin-angiotensin system in immunosuppression of tumor microenvironment
Kenta Nakamura et al.
CANCER SCIENCE (2018)
Angiotensin 1-7 inhibits angiotensin II-stimulated head and neck cancer progression
E. E. Hinsley et al.
EUROPEAN JOURNAL OF ORAL SCIENCES (2017)
Tumour-associated macrophages as treatment targets in oncology
Alberto Mantovani et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Zachary R. Chalmers et al.
GENOME MEDICINE (2017)
Toll-like receptor 5 and 7 expression may impact prognosis of HPV-positive oropharyngeal squamous cell carcinoma patients
Lauri Jouhi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Comprehensive genomic characterization of head and neck squamous cell carcinomas
Michael S. Lawrence et al.
NATURE (2015)
PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPa axis in HPV negative head and neck squamous cell carcinoma
Guang-Tao Yu et al.
ONCOTARGET (2015)
Much more than M1 and M2 macrophages, there are also CD169+ and TCR+ macrophages
Leslie Chavez-Galan et al.
FRONTIERS IN IMMUNOLOGY (2015)
Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma
Simona Partlova et al.
ONCOIMMUNOLOGY (2015)
The Role of Antiangiogenic Agents in the Treatment of Head and Neck Cancer
N. Denaro et al.
ONCOLOGY (2012)
Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors
Benjamin Diop-Frimpong et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells
Pravin J. Mishra et al.
CANCER RESEARCH (2008)
Cytokines in head and neck cancer
Ralph Pries et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2006)
分享论文
